Overcoming Resistance to Osimertinib by T790M Loss and C797S Acquisition Using Gefitinib in a Patient With EGFR-Mutant NSCLC: A Case Report

Overcoming Resistance to Osimertinib by T790M Loss and C797S Acquisition Using Gefitinib in a Patient With EGFR-Mutant NSCLC: A Case Report

Limited strategies are available at disease progression on osimertinib for patients with EGFR-mutant NSCLC. The emergence of the on-target EGFR C797S mutation has been described as one of the most common mechanisms of resistance. In addition, loss of the EGFR T790M mutation has been mainly investiga...

Full description

Bibliographic Details
Main Authors: Diego Enrico, MD, Florencia Tsou, MD, Greta Catani, MD, Carmen Pupareli, MD, María Romina Girotti, PhD, David Esteban Ulloa Alvarez, MD, Federico Waisberg, MD, Andrés Rodríguez, MD, Roxana Reyes, MD, Matías Chacón, MD, Noemí Reguart, MD, PhD, Claudio Martín, MD
Format: Article
Language:English
Published: Elsevier 2023-02-01
Series:JTO Clinical and Research Reports
Subjects:
EGFR
T790M loss
Osimertinib
C797S
Gefitinib
Case report
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364322001801

Similar Items

Similar Items